Max Marchione consistently uses the success of GLP-1 agonists (e.g., Ozempic) to counter the claim that peptides are an inferior drug class. By highlighting that perhaps the most impactful drug of the modern era is a peptide, he argues that the entire category holds immense, untapped potential that cannot be dismissed.

Martin Shkreli claims that from a pharmaceutical development perspective, peptides are often avoided. They possess inherent weaknesses, being more complex than small molecules but less effective than large molecules like antibodies. This makes their recent popularity in biohacking circles ironic to industry insiders.

Martin Shkreli frames the rise of do-it-yourself peptide use not as a scientific movement, but as a psychological one. He argues it's driven by a societal loss of faith in institutions like government and big pharma, coupled with a personal need for control, leading people to reject expert-led medicine for self-experimentation.

The critique of the peptide trend often misses that users aren't taking unknown chemicals. Many use compounds like Retatrutide, which is already in Phase 3 clinical trials by Eli Lilly. They are essentially front-running the FDA approval process for drugs that already have substantial clinical backing.

Martin Shkreli dismisses the biohacking trend of using peptides. He argues that without rigorous data on pharmacokinetics—how a substance is metabolized and its half-life—one doesn't have a medicine, but a delusion. He criticizes enthusiasts for ignoring the foundational science required for any pharmaceutical.

Martin Shkreli posits that the rise of self-experimentation with peptides is fueled by psychological drivers—a desire for personal control, identity, and a fundamental distrust of established institutions like the pharmaceutical industry. This frames the trend as a cultural phenomenon, not purely a medical one.

Martin Shkreli argues the pharmaceutical industry avoids peptides due to inherent weaknesses like short half-lives, viewing them as the 'worst of both worlds' compared to small molecules or antibodies. This perspective reframes the peptide craze as an elevation of a scientifically challenging and often impractical drug class.

Proponent Max Marchione argues the debate isn't between using peptides or not, but between an unsafe gray market and a regulated 'white market.' He contends that since people already use them, legalizing their production in GMP-certified facilities under FDA oversight is the safest path forward to reduce net harm.

Shkreli dismisses the peptide trend popular in tech circles. He contends that without understanding a drug's half-life (pharmacokinetics), its specific biological target, and rigorous double-blind trial data, users are engaging in delusion, not science. He criticizes the dismissal of the FDA and established pharma processes.